- Home
- BANX vs ALDX Comparison
BANX vs ALDX Comparison
Compare BANX & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANX
- ALDX
- Stock Information
- Founded
- BANX 2013
- ALDX 2004
- Country
- BANX United States
- ALDX United States
- Employees
- BANX N/A
- ALDX N/A
- Industry
- BANX Trusts Except Educational Religious and Charitable
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- BANX Finance
- ALDX Health Care
- Exchange
- BANX Nasdaq
- ALDX Nasdaq
- Market Cap
- BANX 146.9M
- ALDX 160.8M
- IPO Year
- BANX N/A
- ALDX 2014
- Fundamental
- Price
- BANX $21.02
- ALDX $4.76
- Analyst Decision
- BANX
- ALDX Strong Buy
- Analyst Count
- BANX 0
- ALDX 2
- Target Price
- BANX N/A
- ALDX $9.50
- AVG Volume (30 Days)
- BANX 23.4K
- ALDX 1.2M
- Earning Date
- BANX 06-17-2025
- ALDX 07-31-2025
- Dividend Yield
- BANX 9.66%
- ALDX N/A
- EPS Growth
- BANX N/A
- ALDX N/A
- EPS
- BANX 2.35
- ALDX N/A
- Revenue
- BANX $29,467,794.00
- ALDX N/A
- Revenue This Year
- BANX N/A
- ALDX N/A
- Revenue Next Year
- BANX N/A
- ALDX N/A
- P/E Ratio
- BANX $8.88
- ALDX N/A
- Revenue Growth
- BANX 2.73
- ALDX N/A
- 52 Week Low
- BANX $17.99
- ALDX $1.14
- 52 Week High
- BANX $21.67
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- BANX 57.31
- ALDX 78.74
- Support Level
- BANX $20.60
- ALDX $4.12
- Resistance Level
- BANX $21.24
- ALDX $4.60
- Average True Range (ATR)
- BANX 0.34
- ALDX 0.29
- MACD
- BANX 0.01
- ALDX 0.08
- Stochastic Oscillator
- BANX 77.32
- ALDX 90.91
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.